Stem cell therapies – treatments that involve the transplantation of stem cells, organs, or other cells into patients to improve the function of diseased or damaged tissues or organs – is a field that has been steadily advancing. Perhaps more than any other industry, stem cell therapies is poised to make a significant near-term impact on worldwide public health, and many individuals living today may experience stem cell-related therapies.
The most obvious use of stem cells is in cell-replacement therapies, but they are also valuable in disease modeling, drug discovery, and drug toxicity assessment. Stem cell therapies are currently being
Stem Cell Research Trial for Congestive Heart Failure
Look what we have here- another stem cell research trial for heart disease (congestive heart failure) and another heart patient has his life improved. This time, at the University of Louisville, the first heart failure patient treated with his own Adult Stem Cells has improved already, […]
Stem Cell Research Debate-Heart Disease Can Be Helped Now
While much of the United States is focused on the debate of Embryonic Stem Cell research versus Adult Stem Cell research, not much attention is given to patients benefiting from Adult Stem Cells right now. The number of patients helped by stem cell therapy for heart […]
Image via Wikipedia
A new therapy based on embryonic stem cells will give a new hope to people who did lose their ability to move in some accident. But that’s not all, because this therapy, developed by the Geron Corp., is the demonstration that in USA, since a few days from Obama‘s election, a new course in research – above all in stem cells research – has begun.
The Food and Drug Administration (FDA) frees the medics to inject spinal stem cells extracted from embryonic tissue in legs paralysed patients since a short time. The treatment in on experimental phase, but
Medistem Inc. announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The clinical trial uses the company’s “Universal Donor” Endometrial Regenerative Cells (ERC) to treat Congestive Heart Failure (CHF).
According to the study design, after 5 patients enter the trial, they must be observed for a two month time period before additional patients are allowed to enter the study. Patient data was analyzed by the study’s independent Data Safety Monitoring Board (DSMB), which concluded that based on lack of adverse effects,